Title: A Randomized, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin (ASA) in Patients with Acute Ischemic Stroke or TIA
[SOCRATES – Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Tricagrelor and Patient Outcomes]
Study Identifier: 2014-066, SOCRATES
Principal Investigator: Brian Scott, MD
Purpose: To learn more about the effectiveness of ticagrelor compared to aspirin for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA).
Summary: This study, sponsored by AstraZeneca, is a randomized, double-blind study comparing the effectiveness of ticagrelor (90mg given twice daily) to aspirin (100mg given once daily) for the prevention of major vascular events in patients with acute ischemic stroke or TIA. Ticagrelor is a platelet aggregation inhibitor that has been FDA-approved for the reduction of cardiovascular events in patients with acute coronary syndrome; however, it is still investigational for the treatment of strokes and TIAs. Subjects will be randomly assigned to either the ticagrelor or aspirin group and will receive the above-mentioned maintenance doses for a period of 90 days. After 90 days, patients will be put on a standard of care antithrombotic drug regimen of the investigator’s choice. Approximately 10 patients will be enrolled at Lahey Hospital & Medical Center.
Study Type: This is an investigational drug study.
Length/Duration: This study lasts for approximately 4 months.
Contact: For more information on this study, please contact the study coordinator at Nicholas.Ventura@lahey.org or 781-744-3216.
For more information on stroke research or for ongoing or upcoming stroke trials, visit www.strokecenter.org.